RNA-based therapeutic development company Ascidian Therapeutics has entered an agreement with global healthcare company Roche to give Roche access to Ascidian's exon-editing platform to develop drugs for undisclosed neurological targets.
As per the agreement, Roche will gain exclusive rights to Ascidian's RNA exon-editing technology, which the companies will develop in collaboration. Roche will continue certain preclinical studies and further clinical development, manufacturing, and commercialization. In return, Ascidian will receive a USD 42 million upfront payment, milestone payments up to USD 1.8 billion, and royalties on sales.
Ascidian Therapeutics is focused on leveraging its proprietary RNA exon-editing technology to target genetic diseases by precisely editing and replacing faulty exons in RNA. Its lead product, ACDN-01, is the first RNA exon editor to enter clinical trials and targets Stargardt disease, a genetic eye disorder. This technology aims to offer the benefits of gene therapy without the risks associated with direct DNA editing, ensuring that normal protein functions are maintained.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.